Pomalidomide in combination with dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Pomalidomide is indicated for the treatment of:
Adult patients with AIDS-related Kaposi sarcoma after failure of highly active antiretroviral therapy (HAART).
Adult patients with Kaposi sarcoma who are HIV-negative.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.